🇺🇸 FDA
Pipeline program

CTX-009

CTX-009-003

Phase 2 small_molecule completed

Quick answer

CTX-009 for Metastatic Colorectal Cancer is a Phase 2 program (small_molecule) at Compass Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Compass Therapeutics
Indication
Metastatic Colorectal Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials